24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias

Hyperkalemia: Pathophysiology & Electrocardiographic Progression

Potassium is the primary intracellular cation, with approximately 98% of total body potassium residing within the intracellular fluid space (intracellular concentration ~140-150 mEq/L vs extracellular concentration 3.5-5.0 mEq/L). The resting membrane potential of cardiac myocytes and excitable tissues is determined by the ratio of intracellular to extracellular potassium, as described by the Nernst equation. Elevating extracellular potassium depolarizes the resting membrane potential (making it less negative), which initially increases myocyte excitability. However, sustained depolarization leads to persistent inactivation of voltage-gated fast sodium channels, causing delayed intracardiac conduction velocity, prolonged repolarization, and eventual complete cardiac arrest.

Severity Classification

• Mild Hyperkalemia: 5.1 to 5.9 mEq/L
• Moderate Hyperkalemia: 6.0 to 6.4 mEq/L
• Severe / Critical Hyperkalemia: >=6.5 mEq/L, OR any serum potassium level associated with electrocardiographic changes.

[!CAUTION] Pseudohyperkalemia Alert: Falsely elevated potassium results from in vitro mechanical lysis of erythrocytes during phlebotomy (excessive tourniquet time, fist pumping, fine needle aspiration, traumatic draw), or severe thrombocytosis (>500,000/uL) and marked leukocytosis (>50,000/uL). If the patient is asymptomatic, has a normal ECG, and has no clinical risk factors (e.g., normal renal function, no potassium-sparing medications), immediately confirm with a repeat non-hemolyzed blood gas or plasma electrolyte specimen drawn without a tourniquet.

Sequential Electrocardiographic Progression

The ECG changes in hyperkalemia follow a characteristic progression reflecting sequential impairment of cardiac conduction systems:

                    ELECTROCARDIOGRAPHIC SEQUENCE IN HYPERKALEMIA

  ┌─────────────────────────┐  ┌─────────────────────────┐  ┌─────────────────────────┐
  │ 1. TALL PEAKED T WAVES  │  │ 2. P WAVE FLATTENING &  │  │ 3. QRS WIDENING &       │
  │    (K+ 5.5 to 6.5 mEq/L)│  │    PR PROLONGATION      │  │    BUNDLE BRANCH BLOCKS │
  ├─────────────────────────┤  ├─────────────────────────┤  ├─────────────────────────┤
  │ • Earliest ECG sign     │  │ • Flattening / loss of P│  │ • QRS widening >120 ms  │
  │ • Narrow base, tented,  │  │ • Lengthening PR interval│ • Intraventricular delays │
  │   symmetric, sharp apex │  │ • Sinoventricular rhythm│  │ • Progressive bradycardia│
  │ • Prominent in V2-V4    │  │ • K+ 6.5 to 7.5 mEq/L   │  │ • K+ 7.0 to 8.0 mEq/L   │
  └─────────────────────────┘  └─────────────────────────┘  └─────────────────────────┘
                                             │
                                             ▼
  ┌───────────────────────────────────────────────────────────────────────────────────┐
  │ 4. SINE WAVE PATTERN (K+ >8.0 mEq/L)                                              │
  │    • Widened QRS complex fuses smoothly with elevated, widened T wave             │
  │    • Smooth, biphasic undulating waveform; extreme pre-terminal emergency         │
  ├───────────────────────────────────────────────────────────────────────────────────┤
  │ 5. TERMINAL DYSRHYTHMIAS (Imminent Cardiac Arrest)                                │
  │    • Ventricular Fibrillation, Pulseless Electrical Activity (PEA), Asystole      │
  │    • Requires immediate CPR and IV Calcium!                                       │
  └───────────────────────────────────────────────────────────────────────────────────┘

1. Tall, Peaked, Symmetric T Waves:
   • Earliest ECG manifestation (typically K+ 5.5-6.5 mEq/L); best seen in precordial leads V2 through V4.
   • Distinctive morphological features: narrow base, sharp symmetric apex, and prominent amplitude ("tented"). Differs from the broad-based, asymmetric hyperacute T waves seen in early acute myocardial infarction.
2. PR Prolongation & Flattening/Loss of P Waves:
   • As potassium rises to 6.5-7.5 mEq/L, atrial myocyte conduction slows.
   • Manifests as lengthening of the PR interval, progressive decrease in P-wave amplitude, and eventual total disappearance of visible P waves (sinoventricular rhythm).
3. QRS Complex Widening & Conduction Delays:
   • As potassium reaches 7.0-8.0 mEq/L, ventricular conduction velocity drops markedly.
   • Manifests as progressive widening of the QRS complex (>120 ms), development of non-specific intraventricular conduction delays, right or left bundle branch block morphologies, and progressive bradycardia.
4. The "Sine Wave" Pattern:
   • Extreme hyperkalemia (typically K+ >8.0 mEq/L) causes the widened QRS complex to merge smoothly with the elevated, widened T wave, creating a dramatic, biphasic undulating sine wave.
   • This is an extreme pre-terminal emergency heralding imminent ventricular fibrillation, pulseless electrical activity (PEA), or asystole.

---

The Emergency Hyperkalemia Treatment Triad

Emergency management of hyperkalemia must proceed through three sequential, non-interchangeable pathophysiologic phases:

                      THE HYPERKALEMIA EMERGENCY TRIAD

    PHASE 1: STABILIZE               PHASE 2: SHIFT                  PHASE 3: ELIMINATE
  ┌─────────────────────┐          ┌─────────────────────┐          ┌─────────────────────┐
  │ Calcium Gluconate   │          │ Regular Insulin 10u │          │ Loop Diuretics      │
  │ 10% 10 mL IV        │          │ + D50W 25 g IV      │          │ (Furosemide 40-80mg)│
  │ (or CaCl 10% in     │   ───►   │ Nebulized Albuterol │   ───►   │ Lokelma / Patiromer │
  │ shock/arrest)       │          │ 10-20 mg            │          │ Emergent Hemodial-  │
  │ Onset: 1-3 min      │          │ IV NaHCO3 (if acid) │          │ ysis (definitive)   │
  │ Duration: 30-60 min │          │ Onset: 15-30 min    │          │ Permanent removal   │
  └─────────────────────┘          └─────────────────────┘          └─────────────────────┘

Phase 1: Myocardial Membrane Stabilization (Immediate Action)

• Indication: Any hyperkalemia with electrocardiographic abnormalities (peaked T waves, QRS widening, sine wave), or serum potassium >=6.5 mEq/L.
• Intravenous Calcium Gluconate 10%:
  • Dose: 10 mL (1 g of calcium gluconate, containing 90 mg [4.6 mEq] elemental calcium) administered IV over 2 to 3 minutes.
  • Access: Preferred for peripheral venous access due to lower risk of severe chemical extravasation necrosis.
  • Repeat Dosing: May repeat dose in 5 to 10 minutes if ECG abnormalities persist or recur.
• Intravenous Calcium Chloride 10%:
  • Dose: 10 mL (1 g of calcium chloride, containing 270 mg [13.6 mEq] elemental calcium—three times more elemental calcium than gluconate).
  • Indication: Preferred in cardiac arrest, profound hypotension, or shock; should be administered via central venous access whenever possible due to severe tissue necrosis and sloughing if extravasated.
• Pharmacodynamics & Mechanism:
  • Onset: 1 to 3 minutes; Duration: 30 to 60 minutes.
  • Mechanism: Antagonizes membrane excitability by shifting the threshold potential of myocytes to a less negative value, restoring the normal electrical separation between resting membrane potential and threshold. Calcium does NOT lower serum potassium levels by a single milliequivalent.

Phase 2: Intracellular Potassium Shifting (Temporary Reduction)

• Regular Insulin PLUS Dextrose:
  • Dose: 10 units Regular Insulin IV PLUS 50 mL of 50% Dextrose (D50W, 25 g dextrose) infused over 5 minutes.
  • Clinical Caveat: If baseline blood glucose is >250 mg/dL, omit the dextrose bolus to prevent extreme hyperosmolality.
  • Mechanism: Insulin binds cell-surface receptors, stimulating the Na+/K+-ATPase pump to drive potassium into skeletal muscle and liver cells.
  • Pharmacodynamics: Onset 15 to 30 minutes; peak effect at 60 minutes; duration 4 to 6 hours. Lowers serum potassium by 0.5 to 1.2 mEq/L.
  • Safety Rule: Monitor capillary blood glucose hourly for at least 4 to 6 hours. Hypoglycemia occurs in up to 10-15% of patients, frequently delayed at 2-3 hours post-administration.
• Inhaled Beta-2 Adrenergic Agonists (Albuterol):
  • Dose: 10 to 20 mg nebulized in 4 mL normal saline over 15 minutes (note: this is 4 to 8 times the standard 2.5 mg bronchodilator dose).
  • Mechanism: Beta-2 adrenergic stimulation increases intracellular cyclic AMP, activating the Na+/K+-ATPase pump.
  • Pharmacodynamics: Onset 15 to 30 minutes; duration 2 to 4 hours. Lowers potassium by 0.5 to 1.0 mEq/L. Has a synergistic, additive effect when combined with insulin.
  • Precautions: Ineffective in ~20% of patients on non-selective beta-blockers; may provoke tachycardia or myocardial ischemia in patients with active coronary artery disease.
• Intravenous Sodium Bicarbonate:
  • Dose: 50 mEq (one 50 mL ampule of 8.4%) IV over 5 minutes.
  • Critical Guideline: Indicated ONLY in patients with concurrent severe metabolic acidosis (bicarbonate <15 mEq/L, pH <7.20). Completely ineffective for shifting potassium in patients with normal acid-base status.

Phase 3: Total Body Potassium Elimination (Definitive Removal)

• Loop Diuretics (Furosemide):
  • Dose: 40 to 80 mg IV (or Bumetanide 1-2 mg IV) in patients with preserved renal function; blocks Na+/K+/2Cl- cotransporter in the loop of Henle, accelerating urinary potassium excretion.
• Gastrointestinal Potassium Binders:
  • Sodium Zirconium Cyclosilicate (Lokelma): 10 g orally three times daily with water for up to 48 hours, followed by 5-10 g daily. Selective inorganic cation exchanger that traps potassium in exchange for sodium and hydrogen throughout the entire gastrointestinal tract. Onset of action within 1 to 2 hours.
  • Patiromer (Veltassa): 8.4 g orally once daily. Non-absorbed polymer that binds potassium in exchange for calcium primarily in the distal colon. Onset of action is 4 to 7 hours; not suitable for hyperacute monotherapy.
  • The Black Box Warning on Kayexalate (Sodium Polystyrene Sulfonate - SPS): SPS, especially when co-administered with sorbitol, carries a severe risk of intestinal necrosis, colonic perforation, and mesenteric ischemia. Its use has been largely superseded by modern binders.
• Emergent Hemodialysis:
  • The gold standard and most definitive therapy for removing total body potassium (clears 25 to 50 mEq of potassium per hour of dialysis).
  • Mandatory in patients with end-stage renal disease (ESRD), oliguric acute kidney injury, extensive tissue necrosis (rhabdomyolysis, tumor lysis syndrome), or hyperkalemia refractory to medical shifting.

---\n

Hypokalemia: Clinical Manifestations, The Magnesium Nexus & Repletion

Severity Classification

• Mild Hypokalemia: 3.0 to 3.4 mEq/L (often asymptomatic or mild fatigue)
• Moderate Hypokalemia: 2.5 to 2.9 mEq/L (muscle weakness, cramps, constipation/ileus)
• Severe Hypokalemia: <2.5 mEq/L (flaccid paralysis, hypoventilation/respiratory failure, tetany, rhabdomyolysis, life-threatening arrhythmias)

Electrocardiographic Findings

Decreasing extracellular potassium hyperpolarizes the resting membrane potential and prolongs ventricular action potential duration:

• T-wave flattening and T-wave inversion;
• ST-segment depression;
• Prominent U waves (positive deflection following the T wave, best visualized in leads V2-V4);
• Apparent QT interval prolongation (which actually represents a fused QU interval);
• Severe dysrhythmias: premature ventricular contractions (PVCs), junctional rhythms, atrial fibrillation, ventricular tachycardia, and torsades de pointes (particularly in patients taking digoxin or antiarrhythmic drugs).

The Critical Magnesium Nexus: Why Hypokalemia Becomes Refractory

Hypokalemia is frequently accompanied by hypomagnesemia (common etiologies include loop/thiazide diuretics, chronic alcohol use, diarrhea, and proton pump inhibitors):

1. ROMK Channel Regulation: In the principal cells of the renal cortical collecting duct, intracellular magnesium acts as a natural, essential physiologic plug that inhibits the renal outer medullary potassium (ROMK) channels.
2. Unchecked Potassium Secretion: When intracellular magnesium is depleted, this inhibitory block is removed. ROMK channels remain persistently open, causing massive, uninhibited potassium secretion into the tubular lumen and wasting into the urine.
3. Pump Dysfunction: Hypomagnesemia impairs the enzymatic function of the Na+/K+-ATPase pump, impairing potassium uptake into cells.

[!IMPORTANT] Board Exam Pearl: Refractory hypokalemia cannot be corrected until coexisting hypomagnesemia is identified and repleted. Always check serum magnesium in patients with hypokalemia; target magnesium >2.0 mg/dL by administering 2 g of IV Magnesium Sulfate over 30 to 60 minutes.

Potassium Repletion Protocols

• Deficit Estimation: For every 1.0 mEq/L drop in serum potassium below 4.0 mEq/L, total body potassium deficit is approximately 100 to 200 mEq (deficits increase exponentially when serum K+ falls <2.5 mEq/L).
• Oral Repletion (Preferred Route):
  • Potassium Chloride (KCl) 20 to 40 mEq orally every 2 to 4 hours (maximum single oral dose 40 mEq to prevent gastrointestinal mucosal irritation).
• Intravenous Repletion (Indications: K+ <2.5 mEq/L, ECG changes, or non-functioning GI tract):
  • Peripheral IV Access: Maximum infusion rate is 10 mEq/h (up to 20 mEq/h in severe emergencies) at a maximum concentration of 40 mEq/L to prevent intense local pain, burning, and chemical phlebitis.
  • Central Venous Access: Infusion rates of 20 to 40 mEq/h can be administered under continuous cardiac telemetry monitoring in an intensive care setting.

---\n

Hyponatremia: Systematic Evaluation & Acute Emergency Protocols

Hyponatremia is defined as a serum sodium concentration <135 mEq/L; severe hyponatremia is defined as <120 mEq/L.

                       DIAGNOSTIC TRIAGE FOR HYPONATREMIA

                              MEASURE SERUM OSMOLALITY
                                         │
        ┌────────────────────────────────┼────────────────────────────────┐
        ▼                                ▼                                ▼
  HYPERTONIC (>295)               ISOTONIC (275-295)               HYPOTONIC (<275)
  • Hyperglycemia (DKA/HHS)       • Pseudohypernatremia            • True Hypotonicity
  • Mannitol infusion             • Severe Hypertriglyceridemia    Assess Clinical
  (Osmotic transcellular shift)   • Paraproteinemia (Myeloma)      Volume Status:
                                                                          │
        ┌─────────────────────────────────────────────────────────────────┼──────────────────────────────┐
        ▼                                                                 ▼                              ▼
  HYPOVOLEMIC                                                       EUVOLEMIC                      HYPERVOLEMIC
  • Urine Na <20: Dehydration, diarrhea, burns                     • SIADH (Urine Osm >100,       • Urine Na <20: CHF,
  • Urine Na >20: Diuretics, Addison disease                         Urine Na >20-40)               Cirrhosis, Nephrotic
  Rx: Isotonic 0.9% Normal Saline                                  • Hypothyroidism, 2° Adrenal   • Urine Na >20: Renal Failure
                                                                   Rx: Fluid Restriction, Vaptans Rx: Loop Diuretics, Fluid Restrict

1. Diagnostic Step 1: Serum Osmolality

• Hypertonic Hyponatremia (>295 mOsm/kg): Caused by osmotically active solutes in the extracellular space (glucose, mannitol) drawing free water out of cells. Calculate corrected sodium.
• Isotonic Hyponatremia (275-295 mOsm/kg): Pseudohyponatremia. Caused by severe hypertriglyceridemia (chylomicronemia) or extreme paraproteinemia (multiple myeloma) displacing aqueous volume. Modern direct ion-selective electrode testing confirms normal physiological sodium.
• Hypotonic Hyponatremia (<275 mOsm/kg): True hypotonic hyponatremia. Proceed to clinical volume assessment.

2. Diagnostic Step 2: Volume Status & Urine Chemistries

• Hypovolemic: Decreased skin turgor, orthostasis, dry mucous membranes, flat neck veins.
  • Urine Sodium <20 mEq/L: Non-renal losses (vomiting, diarrhea, third-spacing, severe burns).
  • Urine Sodium >20 mEq/L: Renal losses (thiazide diuretics, mineralocorticoid deficiency / Addison disease, cerebral salt wasting).
  • Treatment: Volume restoration with Isotonic 0.9% Normal Saline.
• Euvolemic: No edema, normal jugular venous pressure, normal blood pressure.
  • Syndrome of Inappropriate Antidiuretic Hormone (SIADH): Inappropriately concentrated urine (Urine Osmolality >100 mOsm/kg, usually >300 mOsm/kg) with high urine sodium (Urine Na >20-40 mEq/L) in a clinically euvolemic patient with normal adrenal, thyroid, and renal function. Etiologies: small cell lung cancer, SSRIs, carbamazepine, pneumonia, CNS trauma. Treatment: Fluid restriction (500-1000 mL/day), oral salt tablets, loop diuretics, or vasopressin receptor antagonists (tolvaptan).
  • Other Euvolemic Causes: Severe hypothyroidism, secondary adrenal insufficiency, psychogenic polydipsia (Urine Osm <100 mOsm/kg), low solute intake (beer potomania, tea-and-toast diet).
• Hypervolemic: Peripheral edema, ascites, jugular venous distention, pulmonary crackles.
  • Urine Sodium <20 mEq/L: Congestive heart failure, cirrhosis, nephrotic syndrome (decreased effective circulating volume triggers secondary hyperaldosteronism and non-osmotic ADH release).
  • Urine Sodium >20 mEq/L: Acute or chronic end-stage kidney disease.
  • Treatment: Sodium and fluid restriction, loop diuretics.

3. Emergency Management of Acute Severe Symptomatic Hyponatremia

• Clinical Presentation: Severe neurologic symptoms resulting from cerebral edema and increased intracranial pressure: active seizures, coma, obtundation, respiratory depression, tentorial brain herniation.
• The 3% Hypertonic Saline Emergency Regimen:
  • Administer 3% Hypertonic Saline (contains 513 mEq/L Na) as a 100 mL IV bolus over 10 minutes.
  • If severe symptoms persist, repeat the 100 mL bolus up to two additional times (total 300 mL) at 10- to 20-minute intervals.
  • Target Immediate Goal: Elevate serum sodium by 4 to 6 mEq/L acutely. A 4-6 mEq/L elevation reduces brain volume by ~10%, arresting seizures and preventing fatal brainstem herniation.

4. Osmotic Demyelination Syndrome (ODS) & Strict Correction Limits

• Pathophysiology of ODS (Central Pontine Myelinolysis):
  • In chronic hyponatremia (>48 hours), brain cells adapt to hypotonicity by extruding intracellular osmolytes (glutamate, taurine, myoinositol) to minimize brain swelling.
  • If serum sodium is raised too rapidly, extracellular tonicity exceeds intracellular tonicity before brain cells can re-synthesize or take up osmolytes.
  • This rapid osmotic gradient draws water violently out of brain cells, causing acute dehydration of glial cells, disruption of the blood-brain barrier, and oligodendrocyte apoptosis, leading to widespread demyelination—most severely in the central pons.
• Clinical Presentation of ODS:
  • Characteristically manifests 2 to 6 days after over-rapid correction.
  • Symptoms: Dysarthria, dysphagia, horizontal gaze paralysis, spastic quadriparesis, and the catastrophic "locked-in syndrome" (awake, fully conscious, but completely paralyzed except for vertical eye movements).
• The Absolute Correction Limits:
  • Standard Limit: Do NOT exceed an increase of 8 mEq/L in any 24-hour period (and <=14-16 mEq/L in 48 hours).
  • High-Risk Patients (advanced cirrhosis, severe malnutrition, chronic alcoholism, hypokalemia, baseline Na <105 mEq/L): Limit correction to 6 to 8 mEq/L in 24 hours.
• Rescue Protocol for Accidental Over-Correction:
  • If serum sodium rises faster than target limits, immediately stop sodium infusion, initiate IV 5% Dextrose in Water (D5W) at 3 mL/kg/h, and administer Desmopressin (DDAVP) 1 to 2 mcg IV or SC every 6 to 8 hours to arrest water diuresis and re-lower serum sodium back into the safe range.

---\n

Hypernatremia: Free Water Deficit & Controlled Rehydration

Hypernatremia (serum sodium >145 mEq/L; severe >160 mEq/L) universally represents a deficit of free water relative to total body sodium.

Etiologies

• Unreplaced Water Losses: Impaired thirst mechanism or lack of access to water (elderly, infants, intubated patients), fever, sweating, severe burns, osmotic diuresis (DKA, HHS, mannitol).
• Diabetes Insipidus: Inability to concentrate urine due to lack of ADH (Central DI: pituitary surgery, trauma) or renal insensitivity to ADH (Nephrogenic DI: lithium toxicity, hypercalcemia). Hallmark: massive polyuria with inappropriately dilute urine (Urine Osm <300 mOsm/kg).
• Exogenous Sodium Overload (rare): Hypertonic sodium bicarbonate infusions, 3% saline infusions, salt ingestion.

Free Water Deficit Calculation Formula

Free Water Deficit (L) = Total Body Water (TBW) x [(Measured Serum Na+ / 140) - 1]

• Total Body Water (TBW) Constants:
  • Non-elderly males: 0.60 x Weight (kg)
  • Non-elderly females or elderly males: 0.50 x Weight (kg)
  • Elderly females: 0.45 x Weight (kg)

Controlled Rehydration Protocol

• Fluid Selection: Oral or enteral water via nasogastric tube is preferred whenever feasible. If IV fluids are required, use 5% Dextrose in Water (D5W) or 0.45% NaCl.
• Rate Limitation: Correct the free water deficit plus ongoing urinary and insensible losses slowly over 48 to 72 hours.
• Crucial Rate Ceiling: Lower serum sodium at a maximum rate of 10 to 12 mEq/L per 24 hours (0.5 mEq/L per hour).
• Danger of Rapid Correction: Brain cells adapt to chronic hypernatremia by accumulating idiogenic intracellular osmolytes. Overly rapid rehydration shifts water into brain cells, precipitating life-threatening cerebral edema, seizures, permanent neurological damage, and death.